Giannis Mountzios: A very useful prognostic tool for patients under IO
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital, Athens, shared a post on X about a recent paper by Guihong Wan et al., commenting:
“Out in The Lancet Oncology a very useful prognostic tool for patients under Immune Oncology (IO), confirming our clinical experience, Compared with patients without immune-related Adverse Events (irAEs) the clusters dominated by such endocrine and cutaneous toxicities were found to experience improved overall survival, whereas those dominated by such respiratory and neurologic events demonstrated worse outcomes.”
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study published in The Lancet Oncology.
Authors: Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds, Shawn G Kwatra, Yevgeniy R Semenov.
